XML 47 R36.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Hybrid Instruments Liabilities | 12 Months Ended
--- | ---
Dec. 31, 2024
Hybrid Instruments [Abstract] |
Hybrid instruments liabilities | 25. Hybrid instruments liabilities As part of the 2018 Mestrelab Research, S.L. (“Mestrelab”), 2022 PreOmics, 2023 Biognosys, 2023 Zontal and certain other majority owned acquisitions, the Company entered into agreements with the noncontrolling interest holders that provide the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining ownerships for cash at contractually defined redemption values. Refer to Note 2, Summary of Significant Accounting Policies for more information on the Company’s policy on hybrid instruments liabilities. The following table sets forth the changes in hybrid instruments liability (in millions):
Balance at December 31, 2022 |  | $ | 34.2 |
Current period additions |  |  | 36.1 |
Current period adjustments |  |  | (2.1 | )
Foreign currency effect |  |  | 2.3 |
Balance at December 31, 2023 |  |  | 70.5 |
Current period additions |  |  | — |
Current period adjustments |  |  | 24.1 |
Current period settlements (a) |  |  | (13.8 | )
Foreign currency effect |  |  | (2.7 | )
Balance at December 31, 2024 |  | $ | 78.1 |
(a) On October 1, 2024, the call option for Mestrelab was executed, and Bruker acquired the remaining 19.03% of Mestrelab. As a result of the transaction, Bruker has obtained 100% ownership interest in Mestrelab The Level 3 fair value measurements of our hybrid instrument liabilities include the following significant unobservable inputs:
Hybrid Instrument Liabilities | Fair Value as of December 31, 2024 (millions) | Valuation Technique | Unobservable Input | Range | Weighted Average (a)
Put / Call Options | 78.1 | Option Pricing Model | Revenue Risk Premium | 1.6% - 12.6% | 10.70%
|  |  | EBITDA Risk Premium | 10.1% - 25.1% | 21.70%
a) Unobservable inputs were weighted by the relative fair value of the hybrid instrument liabilities.

X
- Definition The entire disclosure for hybrid instruments and embedded derivatives, including discussion of the process used in evaluating whether a hybrid instrument in the form of a share constitutes a debt or equity security, and on what basis an embedded derivative was deemed to be separable or inseparable from the host instrument. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 15 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815-15/tableOfContent + Details
Name: | us-gaap_DiscussionOfHybridInstrumentsAndEmbeddedDerivativesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_HybridInstrumentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration